Korro Bio (KRRO) Preferred Stock Liabilities (2018 - 2022)
Korro Bio's (KRRO) quarterly Preferred Stock Liabilities came in at $57.7 million in Q4 2022, little changed YoY from $57.7 million in Q4 2021, and little changed on a QoQ basis from $57.7 million in Q4 2021.
Korro Bio (KRRO) Preferred Stock Liabilities (2018 - 2022) Analysis & Trends
Korro Bio (KRRO) has 4 years of Preferred Stock Liabilities data on file, last reported at $57.7 million in Q4 2022.
- Quarterly Preferred Stock Liabilities changed 0.0% year-over-year to $57.7 million in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $57.7 million (changed 0.0% YoY) and the FY2022 annual result came in at $57.7 million, changed 0.0% from the prior year.
- Preferred Stock Liabilities held at $57.7 million in Q4 2022, from $57.7 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $147.9 million in Q3 2019 to a low of $46.7 million in Q4 2018.
- A 4-year average of $77.5 million and a median of $57.7 million in 2021 frame the typical range for Preferred Stock Liabilities.
- The widest YoY moves for Preferred Stock Liabilities: up 0.0% in 2022, down 0.0% in 2022.
- Tracing KRRO's Preferred Stock Liabilities over 4 years: stood at $46.7 million in 2018, then jumped by 216.75% to $147.9 million in 2019, then tumbled by 60.99% to $57.7 million in 2021, then changed by 0.0% to $57.7 million in 2022.
- The last three Preferred Stock Liabilities figures came in at $57.7 million (Q4 2022), $57.7 million (Q4 2021), and $147.9 million (Q3 2019), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Korro Bio | 231.77 Mn | 116.73 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 57.70 Mn |
| Dec 31, 2021 | 57.70 Mn |
| Sep 30, 2019 | 147.90 Mn |
| Dec 31, 2018 | 46.69 Mn |